Evotec SE(EVO)Earnings, Financials & Key Ratios
EVO•NASDAQ
$2.71
Price updated Jun 25, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryContract development and manufacturing services
AboutEvotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Show more
- Revenue$757M-5.0%
- EBITDA-$40M+2.8%
- Net Income-$99M+49.3%
- EPS (Diluted)-0.28+50.0%
- Gross Margin8.27%-42.6%
- EBITDA Margin-5.25%-2.3%
- Operating Margin-17.87%
- Net Margin-13.13%+46.6%
- ROE-11.26%+40.5%
EVO Price & Volume
Evotec SE (EVO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Undermine Structural Growth Potential
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Operational scale and liquidity
Key Thesis Takeaways
- Evotec faces a challenging outlook as its reliance on volatile milestone payments leads to inconsistent revenue, evidenced by a 20.4% year-over-year contraction in 2026Q1.
- The company's high-cost infrastructure, characterized by $531.4 million in net PPE, continues to exert significant pressure on profitability and liquidity.
- Investors should remain cautious as the accumulation of an $898.8 million retained earnings deficit suggests long-term value destruction that outweighs the potential of its drug discovery platform.
Verdict Logic
the company's inability to achieve operational self-sufficiency is underscored by a -35.4% operating margin in 2026Q1, indicating significant risk to capital preservation.
EVO Growth Metrics
Evotec SE (EVO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.48%
5 Years8.62%
3 Years0.26%
TTM-5.45%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM5.31%
Return on Capital
10 Years3.25%
5 Years-3.34%
3 Years-6.71%
Last Year-9.09%
EVO Recent Earnings
Evotec SE (EVO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (8%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.48-217.9%
$0.15
Rev
$217M+5.0%
$206M
Q2 2026
Apr 8, 2026Metric
Actual
Est
EPS
$0.05-74.0%
$0.21
Rev
$348M+5.7%
$329M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.14-1.4%
$0.14
Rev
$192M-20.0%
$240M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.14+19.9%
$0.18
Rev
$202M+5.1%
$192M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.48vs $0.15-217.9% | $217Mvs $206M+5.0% |
| Q2 2026 | Apr 8, 2026 | $0.05vs $0.21-74.0% | $348Mvs $329M+5.7% |
| Q4 2025 | Nov 5, 2025 | $0.14vs $0.14-1.4% | $192Mvs $240M-20.0% |
| Q3 2025 | Aug 13, 2025 | $0.14vs $0.18+19.9% | $202Mvs $192M+5.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Evotec SE (EVO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.71 | $962.56M | -8.52 | -4.98% | -13.13% | -11.26% | — | |
| $186.43 | $31.64B | 23.78 | 5.87% | 8.33% | 22.11% | — | |
| $212.71 | $10.25B | -73.10 | -0.85% | -4.59% | -5.66% | — | |
| $519.96 | $14.85B | 34.03 | 19.97% | 17.19% | 120.89% | — | |
| $144.20 | $19.76B | 6466.37 | 2.72% | 3.46% | 2.79% | — | |
| $3.34 | $1.49B | -2.32 | 26.92% | -844.46% | -54.32% | — |
Compare EVO vs Peers
Evotec SE (EVO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EVO Frequently Asked Questions
Evotec SE (EVO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Evotec SE's revenue?
Evotec SE (EVO) reported $745.2M in revenue for fiscal year 2025. This represents a 20757% increase from $3.6M in 2003.
How fast is Evotec SE growing?
Evotec SE (EVO) saw revenue decline by 5.0% over the past year.
Is EVO profitable?
Evotec SE (EVO) reported a net loss of $196.0M for fiscal year 2025.
Dividend & Returns
What is EVO's return on equity?
Evotec SE (EVO) has a return on equity (ROE) of -11.3%. Negative ROE indicates the company is unprofitable.
What is Evotec SE's free cash flow?
Evotec SE (EVO) had negative free cash flow of $44.9M in fiscal year 2025, likely due to heavy capital investments.